Developer of biosimilar theraputics
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States and the positive impact these medications will have for the Medicare and Medicaid programs. FDA's March 31, 2016 Biosimilars Labeling Guidance.

Issues related to Inter Partes Review and its role in ensuring a robust biosimilars market place. 

Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States. FDA's March 31, 2016 Biosimilars Labeling Guidance.

Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States and the positive impact these medications will have on drug cost and access.
MMM - Medicare/Medicaid HCR - Health Issues PHA - Pharmacy
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
NATHANSON+HAUCK
601 13th Street NW, Suite 290 North, Washington, DC, 20005, US
MEGAN HAUCK MARSHALL MELANIE JAN NATHANSON MEGAN HAUCK MARSHALL MELANIE JAN NATHANSON MEGAN HAUCK MARSHALL MELANIE JAN NATHANSON